Emerging evidence supports a complex functional interaction between the Hh/Gli and PI3K/Akt/mTOR pathways in several cancer types, such as melanoma, prostate cancer, glioma, and hematologic malignancies [12,13,14]. Here, MTOR is linked to hematologic disorder.